Figure 4.
AUY922 treatment reduces GVHD against miHAs. Lethally irradiated B6/SJL recipient mice received C3H.SW TCD-BM or TCD-BM plus CD8+ T-cell transplants. Recipients were treated with 14 doses of AUY922 from day 0 to day 27 (A-C) or 12 doses of AUY922 from day 7 to day 29 (D-F) after transplantation, with phosphate-buffered saline treatment as control (Con). (A,D) Survival and clinical score were monitored over time. (B-C,E-F) Tissues were collected on day 22 and later but before day 55 after transplantation. (B,E) Images were obtained with an Olympus BX41 microscope (magnification ×200; hematoxylin-eosin stain). (C,F) Graphs show the histologic score of GVHD. Error bars indicate mean ± standard deviation. Data are representative of 2 to 3 independent experiments *P < .05; **P < .01; ***P < .001.

AUY922 treatment reduces GVHD against miHAs. Lethally irradiated B6/SJL recipient mice received C3H.SW TCD-BM or TCD-BM plus CD8+ T-cell transplants. Recipients were treated with 14 doses of AUY922 from day 0 to day 27 (A-C) or 12 doses of AUY922 from day 7 to day 29 (D-F) after transplantation, with phosphate-buffered saline treatment as control (Con). (A,D) Survival and clinical score were monitored over time. (B-C,E-F) Tissues were collected on day 22 and later but before day 55 after transplantation. (B,E) Images were obtained with an Olympus BX41 microscope (magnification ×200; hematoxylin-eosin stain). (C,F) Graphs show the histologic score of GVHD. Error bars indicate mean ± standard deviation. Data are representative of 2 to 3 independent experiments *P < .05; **P < .01; ***P < .001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal